Literature DB >> 17039261

Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.

Ji Hyeon Ju1, Seung-Ki Kwok, Soo-Hong Seo, Chong-Hyeon Yoon, Ho-Youn Kim, Sung-Hwan Park.   

Abstract

Behçet's disease is a chronic, relapsing, multisystem inflammatory disorder characterized predominantly by recurrent orogenital ulcers, skin involvement, and uveitis. Recurrent mucocutaneous lesions may be the only symptom in mild cases, but ocular, gastrointestinal, and central nervous system involvement may occur in severe cases. We report in this study the successful treatment with infliximab of severe life-threatening GI bleeding caused by an ileal ulcer in a patient with Behçet's disease. Antitumor necrosis factor (TNF) therapy could be an emergency therapeutic option in patients with massively bleeding Behçet's disease and unstable patients or those with acute bleeding with other TNF-alpha-mediated autoimmune diseases. Another option for anti-TNF therapy could be as bridging management between conservative and surgical treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17039261     DOI: 10.1007/s10067-006-0410-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab.

Authors:  Thomas Mussack; Nikola Landauer; Roland Ladurner; Uwe Schiemann; Manuela Goetzberger; Christian Burchardi; Christian Folwaczny; Walter Heldwein; Klaus Hallfeldt
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

2.  Successful treatment of genital ulcers with infliximab in Behcet's disease.

Authors:  G Haugeberg; M Velken; V Johnsen
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease.

Authors:  K Masuda; A Nakajima; A Urayama; K Nakae; M Kogure; G Inaba
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

5.  Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report.

Authors:  P V Hassard; S W Binder; V Nelson; E A Vasiliauskas
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

6.  Anti-TNF-alpha therapy for sight threatening uveitis.

Authors:  E W Lindstedt; G S Baarsma; R W A M Kuijpers; P M van Hagen
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

7.  Intestinal involvement in Behçet's disease: review of 136 surgical cases in the Japanese literature.

Authors:  Y Kasahara; S Tanaka; M Nishino; H Umemura; S Shiraha; T Kuyama
Journal:  Dis Colon Rectum       Date:  1981 Mar-Apr       Impact factor: 4.585

8.  Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

Authors:  P P Sfikakis; P G Theodossiadis; C G Katsiari; P Kaklamanis; N N Markomichelakis
Journal:  Lancet       Date:  2001-07-28       Impact factor: 79.321

9.  Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.

Authors:  S P Travis; M Czajkowski; D P McGovern; R G Watson; A L Bell
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

  9 in total
  8 in total

Review 1.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

2.  Mimicry and deception in inflammatory bowel disease and intestinal behçet disease.

Authors:  Erika L Grigg; Sunanda Kane; Seymour Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

3.  Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.

Authors:  Sook Hee Chung; Soo Jung Park; Sung Pil Hong; Jae Hee Cheon; Tae Il Kim; Won Ho Kim
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

4.  Animal Models in Behçet's Disease.

Authors:  Ozlem Yildirim
Journal:  Patholog Res Int       Date:  2012-02-27

5.  The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.

Authors:  Tadakazu Hisamatsu; Fumiaki Ueno; Takayuki Matsumoto; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Fumihito Hirai; Masakazu Nagahori; Mitsunobu Matsushita; Kenji Kobayashi; Mitsumasa Kishimoto; Mitsuhiro Takeno; Masanori Tanaka; Nagamu Inoue; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2013-08-18       Impact factor: 7.527

6.  Ileocecal ulcers accompanied by relapsing polychondritis: a case report.

Authors:  Yoko Kawakami; Katsuya Endo; Tomonori Ishii; Sho Haneda; Fumiyoshi Fujishima; Yoichi Kakuta; Hisashi Shiga; Yoshitaka Kinouchi; Tooru Shimosegawa
Journal:  Springerplus       Date:  2014-12-07

Review 7.  Outcome predictors for intestinal Behçet's disease.

Authors:  Jae Jun Park; Won Ho Kim; Jae Hee Cheon
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

8.  Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.

Authors:  Yue Li; Zelong Han; Xianfei Wang; Zhihui Mo; Wei Zhang; Aimin Li; Side Liu
Journal:  BMC Gastroenterol       Date:  2013-12-09       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.